|
TNF-α
|
[123]
|
RT
|
HNC
|
Saliva
|
High
|
No
|
| |
[124]
|
RT
|
HNC
|
Cytologic smears from oral cavity
|
High
|
Association with OM development
|
| |
[125]
|
RT, RT + CT
|
HNC
|
Serum
|
Low
|
No
|
| |
[126]
|
RT, RT + CT
|
HNC
|
Serum
|
Low
|
No
|
|
IL-1
|
[125]
|
RT, RT + CT
|
HNC
|
Serum
|
No change
|
No
|
| |
[126]
|
RT, RT + CT
|
HNC
|
Serum
|
No change
|
No
|
|
IL-1β
|
[124]
|
RT
|
HNC
|
Cytologic smears from oral cavity
|
High
|
Association with OM development
|
|
IL-6
|
[123]
|
RT
|
HNC
|
Saliva
|
High
|
Association with OM severity
|
| |
[125]
|
RT, RT + CT
|
HNC
|
Serum
|
High
|
Association with OM severity
|
|
IL-8
|
[123]
|
RT
|
HNC
|
Saliva
|
High
|
No
|
| |
[125]
|
RT, RT + CT
|
HNC
|
Serum
|
High
|
No
|
|
IL-10
|
[123]
|
RT
|
HNC
|
Saliva
|
High
|
Association with OM severity
|
| |
[125]
|
RT, RT + CT
|
HNC
|
Serum
|
No change
|
No
|
|
TGF-β
|
[127, 128]
|
RT + CT
|
HNC
|
Plasma
|
High
|
Association with OM severity
|
|
EGF
|
[2, 129, 130]
|
RT
|
HNC
|
Saliva
|
Low
|
Association with OM development
|
| |
[131]
|
RT
|
HNC
|
Saliva
|
Low
|
Association with OM development
|
|
CRP
|
[132]
|
RT
|
HNC
|
Blood
|
High
|
Association with OM severity
|
| |
[133]
|
RT
|
HNC
|
Blood
|
High
|
Not assessed
|
| |
[134]
|
RT, RT + CT
|
HNC
|
Blood
|
High
|
Not assessed
|
| |
[135]
|
RT + CT
|
HNC
|
Blood
|
High
|
Association with OM severity only at initial week
|
|
ESR
|
[132]
|
RT
|
HNC
|
Blood
|
High
|
No
|
| |
[134]
|
RT, RT + CT
|
HNC
|
Blood
|
High
|
Not assessed
|
| |
[135]
|
RT + CT
|
HNC
|
Blood
|
High
|
No
|
|
GSH
|
[136]
|
RT
|
Oral cavity cancer
|
Plasma
|
Measured before RT
|
GSH baseline levels associate with OM development
|
| |
[137]
|
RT
|
HNC
|
Plasma
|
No change
|
No
|
|
DNA DSB (γ-H2AX)
|
[138]
|
RT
|
HNC
|
Peripheral blood lymphocytes
|
High
|
Association with OM severity
|
| |
[139]
|
RT, RT + CT
|
HNC
|
Peripheral blood lymphocytes
|
High
|
No
|
